Participation in Key Conferences
Pyxis Oncology, Inc. (Nasdaq: PYXS), a pioneering clinical-stage company specializing in antibody-drug conjugate (ADC) therapeutics aimed at challenging cancers, has recently announced participation in several notable conferences that investors and industry professionals should not miss.
Upcoming Investor Conferences
During these engagements, Lara S. Sullivan, M.D., the accomplished President and CEO of Pyxis Oncology, will be at the forefront, actively participating in the following investor events:
2025 Cantor Global Healthcare Conference
This highly anticipated conference will take place in New York City on a selected Wednesday in September, with a scheduled fireside chat at 2:45 p.m. ET, alongside opportunities for one-on-one investor meetings.
H.C. Wainwright 27th Annual Global Investment Conference
Another significant event will be hosted the following Monday in September, where Dr. Sullivan will once again participate in a fireside chat and exclusive discussions with investors at 10:30 a.m. ET.
Industry Engagements
It’s not just investor meetings for Pyxis. The company is also gearing up for an essential industry conference:
2nd Annual ADC and Novel Conjugates Partnering and Investment Summit
On a Tuesday in September, Pyxis will present at this summit specific to ADCs in Boston. The company will showcase its pioneering research without a webcast option, allowing direct engagement with attendees at 3:20 p.m. ET.
Accessing Live Webcasts
In addition to in-person presentations, stakeholders can look forward to live webcasts and replays of the fireside chats from the Cantor and H.C. Wainwright conferences. These sessions will be accessible through the Investor Relations section on the Pyxis Oncology website, ensuring that interested parties remain informed on the company’s latest developments.
About Pyxis Oncology, Inc.
At the core of its mission, Pyxis Oncology is dedicated to developing innovative treatment options for challenging and hard-to-treat cancers. The company is at the forefront of creating advanced therapies that have shown promise in diverse settings, including monotherapy and combination therapies. Its leading candidate, micvotabart pelidotin (MICVO), has been undergoing rigorous evaluation in various ongoing Phase 1 clinical studies across multiple solid tumor types. The focus is heavily directed toward recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) due to a compelling signal from preliminary studies.
Moreover, Pyxis has initiated a Phase 1/2 combination trial using MICVO along with Merck's renowned anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). This innovative approach hopes to address patients battling R/M HNSCC and several other advanced solid tumors. The implications of these studies could be transformative for cancer therapy.
Contact Information
If you wish to learn more about Pyxis Oncology or have inquiries, feel free to reach out:
Pyxis Oncology Contact
Jitu Wadhane
Principal Financial and Accounting Officer
Email: IR@pyxisoncology.com
Media Contact
Molly Devlin
Real Chemistry
Email: mdevlin@realchemistry.com
Frequently Asked Questions
What is Pyxis Oncology known for?
Pyxis Oncology is recognized for developing innovative antibody-drug conjugate (ADC) therapeutics aimed at treating difficult cancers.
Who will represent Pyxis Oncology at the conferences?
Dr. Lara S. Sullivan, the President and CEO, will represent Pyxis Oncology at the upcoming conferences.
What are the notable upcoming conferences for Pyxis Oncology?
Key conferences include the Cantor Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference.
When will the company present?
Presentations will occur in early September, with specific times listed for each event.
How can I learn more about Pyxis Oncology?
More information about Pyxis Oncology can be found on their official website and through their Investor Relations section.
